What is the difference between the bivalent, quadrivalent and nine-valent cervical cancer vaccines?

The difference between bivalent, quadrivalent and nine-valent cervical cancer vaccines mainly lies in the number of HPV virus types they prevent and the range of diseases they cover. The bivalent vaccine targets HPV types 16/18, the quadrivalent vaccine covers HPV types 6/11, and the nine-valent vaccine covers HPV types 6/11/16/18/31/33/45/52/58, preventing cervical cancer, genital warts and other diseases.

One and two-valent vaccines

The bivalent cervical cancer vaccine mainly prevents HPV type 16 and type 18 infections. These two high-risk HPV types cause about 70% of cervical cancer cases. The vaccine is suitable for women aged 9-45 and requires three doses, with intervals of 0, 1, and 6 months. The bivalent vaccine has a significant protective effect against cervical precancerous lesions, but has no cross-protective effect against other HPV types. Minor adverse reactions such as local redness, swelling, and fever may occur after vaccination, which usually resolve spontaneously within a short period of time.

Second, quadrivalent vaccine

The quadrivalent cervical cancer vaccine adds protection against HPV types 6 and 11, which are two low-risk HPV types that cause genital warts. The vaccination age range is 9-45 years old, and three doses are also required. In addition to preventing cervical cancer, the quadrivalent vaccine can also reduce the risk of anal cancer, vulvar cancer and genital warts. Its adverse reactions are similar to those of the bivalent vaccine, including pain at the injection site or temporary fever. The overall safety profile is good.

3. Nine-valent vaccine

The nine-valent cervical cancer vaccine covers nine HPV types, including seven high-risk types (16/18/31/33/45/52/58) and two low-risk types (6/11). It can prevent about 90% of cervical cancer and 90% of genital warts. Applicable to women aged 16-26, the vaccination schedule is three doses. The nine-valent vaccine also has a protective effect against vaginal cancer, vulvar cancer and anal cancer. It is currently the HPV vaccine with the widest coverage. After vaccination, it is necessary to observe whether allergic reactions occur, and people with severe immune deficiency should use with caution.

4. Differences in Applicable Groups

Bivalent and quadrivalent vaccines are suitable for a wider age group and are suitable for women aged 9-45 years.； The nine-valent vaccine is currently only approved for use in women aged 16-26. For people who have been sexually active or have been exposed to HPV, the vaccine can still provide protection against the uninfected type. Pregnant women should postpone vaccination, and lactating women should be carefully evaluated. Men's vaccination with the quadrivalent or nine-valent vaccine can prevent genital warts and anal cancer, but currently only women are approved for vaccination in China.

5. Comparison of protective effects

The protective efficacy of bivalent vaccine against cervical precancerous lesions related to HPV type 16/18 exceeds 90%； The quadrivalent vaccine is more than 90% effective in preventing genital warts ； The nine-valent vaccine increases the cervical cancer protection rate to 90% and provides more comprehensive protection against various HPV-related cancers. All three vaccines require a full course of vaccination to obtain the best immune effect, and antibodies can last for at least 10 years. Regular cervical cancer screening is still required after vaccination, as the vaccine cannot clear existing HPV infection.

No matter which HPV vaccine is chosen, it is recommended to receive it before HPV exposure for maximum protection. After vaccination, maintain a healthy lifestyle and avoid high-risk behaviors such as smoking and multiple sexual partners. Regular cervical cytology examinations are performed, and it is recommended that women over 30 years old undergo combined HPV testing. If persistent high fever or severe allergic reaction occurs after vaccination, you should seek medical evaluation promptly. Vaccines cannot replace routine screening, and the combination of the two can significantly reduce the risk of cervical cancer.